Chemotherapy Induced Neutropenia (CIN) Market Set to See Growth from Biosimilar G-CSF Adoption

Chemotherapy Induced Neutropenia (CIN) Market Set to See Growth from Biosimilar G-CSF Adoption

Chemotherapy induced neutropenia (CIN) refers to the dangerously low neutrophil counts that result from cytotoxic cancer treatments, leaving patients vulnerable to severe infections and treatment delays. Products addressing CIN include granulocyte colony-stimulating factors (G-CSFs) such as filgrastim, pegfilgrastim, and emerging biosimilars designed to shorten neutropenia duration, reduce infection-related hospitalizations, and maintain planned chemotherapy dose intensity. These agents offer advantages in terms of improved safety profiles, fewer febrile neutropenia episodes, and enhanced quality of life. With mounting evidence from clinical trials underscoring reduced treatment-related complications, oncology centers worldwide are integrating G-CSF therapies into standard practice.  

Chemotherapy Induced Neutropenia (CIN) Market growing focus on personalized cancer care, coupled with advancements in biosimilar manufacturing, has driven down therapy costs and expanded access in both developed and emerging markets. As payers and providers prioritize health economics and patient outcomes, the CIN market continues to witness robust market growth, reflecting broader industry trends toward value-based care and targeted supportive oncology.

The chemotherapy induced neutropenia (CIN) market is estimated to be valued at USD 14.88 Bn in 2025 and is expected to reach USD 21.08 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

Key Takeaways

Key players operating in the Chemotherapy Induced Neutropenia (CIN) Market are

·         Amgen Inc.

·         Sandoz

·         Teva Pharmaceutical Industries Ltd.

·         Coherus BioSciences

·         Mylan N.V.

These market leaders dominate through extensive R&D investment, a diversified product portfolio, and strategic licensing agreements for biosimilars. Amgen’s flagship pegfilgrastim and filgrastim products hold substantial market share, while Sandoz and Teva leverage cost-effective filgrastim biosimilars to challenge established incumbents. Coherus BioSciences has carved out a niche with innovative delivery devices, and Mylan N.V. continues to expand its pipeline via acquisitions. Collectively, these market players engage in ongoing clinical trials, collaborate with academic centers, and pursue regulatory approvals across multiple regions, reinforcing the competitive landscape and underpinning future market insights. Their combined activities feature heavily in industry reports, guiding stakeholders on market dynamics, growth strategies, and consolidation trends.

The CIN market presents significant market opportunities driven by rising cancer incidence, increasing adoption of biosimilars, and unmet needs in emerging economies. Advances in pharmacogenetics and diagnostic assays are enabling more precise patient stratification, thus opening avenues for tailored G-CSF dosing regimens. Manufacturers can capitalize on the shift toward home-care delivery models by developing user-friendly auto-injectors and on-body wearables that support outpatient administration. Furthermore, integrating digital health solutions for monitoring neutrophil counts and patient adherence can foster new service-based revenue streams. In parallel, public–private partnerships and government initiatives in Asia Pacific and Latin America aim to enhance access to supportive oncology, representing lucrative avenues for market expansion and business growth.

Global expansion remains a focal market trend, with North America continuing to dominate revenue generation due to a well-established healthcare infrastructure, favorable reimbursement policies, and high physician awareness of CIN management guidelines. Europe follows closely, buoyed by regulatory harmonization via the EMA and strong uptake of biosimilar G-CSFs in cost-containment strategies. However, the fastest growth rates are anticipated in Asia Pacific and Latin America, where rising healthcare expenditure, expanding hospital networks, and increasing market scope for oncology drugs are driving demand. Market research indicates that key players are forging regional partnerships and local manufacturing alliances to navigate regulatory challenges and tailor market access strategies, ensuring broad geographic coverage and improved patient outcomes across diverse markets.

Market Drivers

One of the primary market drivers is the increasing adoption of biosimilar granulocyte colony-stimulating factors (G-CSFs). As patents for originator filgrastim and pegfilgrastim have expired, biosimilars have entered the market offering cost savings of up to 30–50 % compared with branded counterparts. This market driver is underpinned by robust clinical data demonstrating comparable efficacy and safety profiles between biosimilars and originator products, fostering physician confidence and payer support. The lower price point of biosimilars enables broader market penetration, particularly in cost-sensitive healthcare systems and emerging markets, thereby driving overall market growth. In addition, streamlined regulatory pathways for biosimilar approvals have accelerated product launches, expanded the number of market players, and intensified competition—leading to downward pressure on treatment costs and increased accessibility. Collectively, these factors enhance market dynamics by widening patient access to CIN therapies, optimizing treatment protocols, and contributing to the overall expansion of the chemotherapy support market segment.

Market Restraint
High treatment costs and reimbursement challenges represent a significant market restraint for CIN therapies. Despite price reductions with biosimilars, the overall expense associated with G-CSF administration—including drug acquisition, nursing support, and patient monitoring—remains substantial. In many regions, limited healthcare budgets and stringent reimbursement policies restrict formulary inclusion, leading to suboptimal uptake of prophylactic G-CSF regimens. Out-of-pocket expenses for patients can be prohibitive, particularly in low- and middle-income countries where insurance coverage is sparse.

Moreover, budgetary constraints in public healthcare systems force providers to prioritize acute treatment interventions over supportive care, curbing the utilization of neutropenia-preventive therapies. This financial barrier not only impacts market revenue but also hinders efforts to standardize CIN management protocols. As a result, the market faces challenges in achieving uniform growth, with accessibility and affordability issues dampening the full realization of CIN treatment benefits.

Segment Analysis

By Prophylactic Agent Type
The chemotherapy-induced neutropenia market segments into conventional granulocyte colony-stimulating factors (G-CSFs) and PEGylated G-CSFs, with the latter commanding the largest market share. PEGylated G-CSFs dominate because they offer extended half-life, reduced injection frequency and improved patient compliance, which align with prevailing market trends toward convenience and outpatient care. Leading market players such as Amgen Inc. (Neulasta®) and Coherus BioSciences have driven significant uptake through robust clinical data and aggressive market growth strategies.

These agents not only address key market challenges—like high hospitalization costs and infection risks—but also capitalize on market opportunities by enabling same-day administration protocols that reduce overall healthcare burden. From a market dynamics perspective, favorable reimbursement policies in major territories and a strong pipeline of biosimilars further bolster PEGylated G-CSF’s dominance. Conventional G-CSFs retain relevance in cost-sensitive markets where healthcare budgets are constrained, yet they trail in revenue generation due to shorter dosing intervals and less convenient administration. Market insights suggest that ongoing innovations in delivery mechanisms and biosimilar launches will sustain PEGylated formulations’ leadership through the forecast period by catering to both clinician preferences and patient-centric treatment models.

Global Analysis

North America currently leads the chemotherapy-induced neutropenia market, owing to well-established healthcare infrastructure, high awareness of neutropenia management guidelines and the presence of key market players investing heavily in R&D. The United States contributes the bulk of industry share, driven by early adoption of novel prophylactic agents and strong reimbursement frameworks. Europe follows closely, benefiting from coordinated regulatory pathways and growing collaborations among market companies to expand biosimilar portfolios.

However, Asia-Pacific is the fastest growing region, fueled by rising cancer incidence, expanding healthcare expenditure and improving market access in countries such as China, India and Japan. Market drivers in Asia-Pacific include government initiatives to enhance oncology care, increasing private-sector participation and growing patient affordability. Latin America and Middle East & Africa exhibit moderate growth as they overcome market restraints related to limited reimbursement and infrastructure gaps. Across all regions, evolving market dynamics—such as heightened focus on outpatient treatment models and digital health integration—are shaping regional market trends. These developments present significant market opportunities for both established players and new entrants looking to address unmet needs in neutropenia prophylaxis.

➢Get this Report in Japanese Language: 化学療法誘発性好中球減少症（CIN）市場

➢Get this Report in Korean Language:  화학요법유도호중구감소증(CIN)시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)